A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma
- Conditions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06337617
- Locations
- 🇨🇳
Novartis, Shanghai, China
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06335979
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06331312
- Locations
- 🇺🇸
Accurate Clinical Research Inc, San Antonio, Texas, United States
🇺🇸Clinical Research Institute of Michigan LLC, Saint Clair Shores, Michigan, United States
🇨🇭Novartis Investigative Site, St Gallen, Switzerland
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2610
- Registration Number
- NCT06311383
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT06293365
- Locations
- 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸Advanced Medical Research, La Palma, California, United States
🇺🇸Conquest Research, Winter Park, Florida, United States
Revolade Tablets Specified Drug-use Survey
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT06287268
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Specified Drug-use Survey of Leqvio for s.c. Injection.
- Conditions
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 560
- Registration Number
- NCT06275724
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
- Conditions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 613
- Registration Number
- NCT06271369
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06267560
- Locations
- 🇺🇸
Inpatient Research Clinical LLC, Miami Lakes, Florida, United States
🇺🇸DBC Research USA, Pembroke Pines, Florida, United States
🇺🇸Grady Health System, Atlanta, Georgia, United States
Special Drug Use-results Surveillance of Tafinlar/Mekinist
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06262919
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan